Effect of dapagliflozin on serum magnesium in HNF1ß patients with renal hypomagnesemia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518855-43-00

Acronym

112930

Enrollment

Registered

2024-11-22

Start date

Unknown

Completion date

2025-05-01

Last updated

2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypomagnesemia due to HNF1beta mutation

Brief summary

Change in serum magnesium

Interventions

DRUGDAPAGLIFLOZIN

DRUGPLACEBO

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in serum magnesium	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026